홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

1-(5-히드록시헥실)-3,7-디메틸-퓨린-2,6-디온

Lisofylline

HCID 501254
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
100324-81-0
표준 SMILES
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
InChIKey
NSMXQKNUPPXBRG-SECBINFHSA-N
분자식
C13H20N4O3
평균 분자량
280.32 g/mol
단동위원소 질량
280.15354051

개요

(R)-lisofylline is a 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (R)-configuration. A synthetic small molecule which was under development for the treatment of type 1 diabetes mellitus. It has a role as an immunomodulator and an anti-inflammatory agent. It is an enantiomer of a (S)-lisofylline.

이름 및 식별자

우선 이름
Lisofylline
IUPAC
1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
현지명
1-(5-히드록시헥실)-3,7-디메틸-퓨린-2,6-디온
영어명
1-(5-hydroxyhexyl)-3,7-dimethyl-purine-2,6-dione
분자식
C13H20N4O3
분자량
280.32

이름 및 동의어

(R)-LisofyllineLISOFYLLINE100324-81-0ProTecLisophyllineCT-1501RlisofilinaCT 1501R1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dioneLisofylline, (r)-lisofyllinumCT1501R
이름 더 보기
1-(5-히드록시헥실)-3,7-디메틸-퓨린-2,6-디온(R)-Lisofylline, 10 mM in DMSO1-(5-hydroxyhexyl)-3,7-dimethyl-purine-2,6-dione3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-diMethyl-(R)-1-(5-Hydroxyhexyl)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione
(R)-Lisophylline1-[(R)-5-hydroxyhexyl]theobromine1-(5R-Hydroxyhexyl)-3,7-dimethylxanthineDTXSID7058709CHEBI:143527L1F2Q2X9561-((R)-5-Hydroxyhexyl)theobromine1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

데이터베이스 식별자

CAS
100324-81-0
PubChem CID
501254
DTXSID
DTXSID7058709
ChEMBL
CHEMBL1411
ChEBI
CHEBI:143527
UNII
L1F2Q2X956
Nikkaji
J731.039K

물성

구조 계산 물성

XLogP
0.7
극성 표면적
78.7 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
4
회전 가능 결합 수
5
무거운 원자 수
20
형식 전하
0
복잡도
390

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Metabolite of Pentoxifylline

물리화학적 성질

녹는점
105 · 105-107°C
끓는 점
511.2 · 511.2±56.0 °C(Predicted)
밀도
1.32 · 1.32±0.1 g/cm3(Predicted)
저장 조건
-20 °C · Hygroscopic, -20°C Freezer, Under Inert Atmosphere
용해도
클로로포름, 메탄올에 용해됨
물리적 상태
고체
산도 계수 (pKa)
15.22 · 15.22±0.20(Predicted)
색상
흰색에서 황백색까지
안정성
흡습성

화학적 성질

White Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302

화학 및 산업

약리 정보

Metabolism/MetabolitesLisofylline has known human metabolites that include pentoxifylline and lisofylline 4,5-diol.
MeSH Pharmacological Classification · 4건

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.

관련 반응

2건
반응 기록 만들기
HRID 348782 반응식
HRID 348782반응물로
HRID 553329 반응식
HRID 553329반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트